about
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionEfficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolismA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.Breaking down the barriers: challenges with development and implementation of an industry-sponsored antimicrobial stewardship data collection and analysis tool.Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations.Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.A survey of pharmacy students' experiences with gamblingAntiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in miceAntimicrobial treatment of asymptomatic bacteriuria in noncatheterized adults: a systematic review.Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's diseaseDevelopment and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatmentTopical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse ModelNanotechnology: a focus on nanoparticles as a drug delivery system.Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option.Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.Hepatitis C therapy: Looking toward interferon-sparing regimens.Natural polyphenols: potential in the prevention of sexually transmitted viral infections.Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis.Evaluation of Staphylococcus aureus Bacteremia: Academic and Community-Based Management Within the Same Health System.Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.Education and Communication in an Interprofessional Antimicrobial Stewardship Program.Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells.Direct differentiation of adult ocular progenitors into striatal dopaminergic neurons.Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter.Regulation of retinal morphology and posterior segment amino acids by 8-isoprostaglandin E2 in bovine eyes ex vivo.Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.Nurse satisfaction using insulin pens in hospitalized patients.Preprinted risk assessment and prophylaxis order form for venous thromboembolism.Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report.Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease.A randomized trial of the peri-operative use of COX-2 inhibitors in Lichtenstein herniorrhaphy.Role of prostanoid production and receptors in the regulation of retinal endogenous amino acid neurotransmitters by 8-isoprostaglandin E2, ex vivo.Antiretroviral nanoparticles: an extended drug delivery modality.
P50
Q27318354-7978D9FE-47EE-43AB-9931-F78F3C32AE16Q28319077-3D54FC79-4404-4313-A4C4-7C9E70E94AE2Q30431343-18B40E51-18C3-4887-90E0-571F9411DB9BQ30479638-AED90608-8524-456B-B4C0-DF7B32E625CAQ30855496-74BC45C2-4CA0-4976-A36A-CBE9B9CF3FA8Q33213321-25554C16-1013-4AD8-81F7-91A05C3B565DQ33517859-5830AD43-B1C3-4EA4-BA41-DB69E3A02948Q33796841-C7F51B26-481A-4446-A03D-630179F14A75Q34138487-6D2BA032-3B2D-4689-B708-2851AB5BAEF6Q35164922-40FA4DC2-1748-4787-9915-9A8F64AD445EQ35314702-E632FA0A-8B29-4364-BD8F-D4D67D9092B1Q35320917-FAF5C0BD-4290-4D92-B414-E5964BF4EE6EQ36442232-B3DA2583-3942-403C-B7D5-162424044E7CQ36795898-6744CA7C-A8B1-48F4-A0F0-CB713A200EA7Q36933427-825AF71A-FCF1-4B0F-8C1A-0E25EB19A514Q37015442-50159C95-BA6E-42B1-A1AD-555015A76DB2Q37395149-0C774D61-D2A5-4E3C-AD11-ECB837151D36Q37538618-8656A8BB-DB01-44D2-8AE0-CDFA5C4CAB20Q37715012-D9735364-CC97-45D1-8FE6-B32436FB84C2Q38239999-C6EFFE86-3E77-4882-90BB-F32E74BCCEA7Q38346567-9DFE0C2D-41E3-4A10-A03E-0678220EB132Q38627591-1839615E-BC65-4C43-9D3A-3795A7550C0FQ38730680-2B4A6956-47D7-4BBF-A5EF-51D8F20155D4Q40293945-174C6E67-0424-434C-902B-8994421BCCFDQ40295877-A700C404-CB0B-4EE9-9795-05E33C01A0FCQ40358789-A68A81F4-5D26-4A79-B71B-4BD93BC1F60EQ40559936-B84C5D3B-6E3F-4B83-8FAD-93FD16DF6357Q40585903-6BFABBC3-9B25-469A-BDF2-0ED9C1880D3FQ41084513-6897706F-B67E-49DE-9625-B5716FC8BDDDQ41154991-904B27D7-2249-46D4-AE26-FC5965BC4706Q41724465-1CDE6CAF-5CC2-4DFD-96A0-375CADE21F86Q42446728-083BC5BA-5546-4241-B340-DA80985B4A80Q43216237-9D61AD3B-8F70-4308-AB69-1501A83495EAQ44146134-2807AF25-E6C9-4B49-8A8C-E39419DB4478Q44681353-CEA8483E-A41A-449C-9A07-9B49618F5322Q44737877-37F9B2B3-E427-425B-9A97-ADB7E8806842Q45269942-1FE2EAA9-4EB8-41C4-B05D-66FEF4F9DD42Q45419481-B877E019-E1CB-4922-A1AB-CD37EF654FEEQ45975215-7D59D272-9318-4CAE-84B6-62C8B02B1692Q46035288-37158C33-1325-4091-B08D-7056ACDFBC16
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Christopher Destache
@ast
Christopher Destache
@en
Christopher Destache
@es
Christopher Destache
@nl
Christopher Destache
@sl
type
label
Christopher Destache
@ast
Christopher Destache
@en
Christopher Destache
@es
Christopher Destache
@nl
Christopher Destache
@sl
prefLabel
Christopher Destache
@ast
Christopher Destache
@en
Christopher Destache
@es
Christopher Destache
@nl
Christopher Destache
@sl
P1053
A-7537-2009
P106
P1153
35268631600
P21
P31
P3829
P496
0000-0001-7923-3939